X

Trial Profile

Efficacy and safety of combination loratadine/montelukast QD [once daily] vs pseudoephedrine and placebo in the treatment of subjects with seasonal allergic rhinitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Loratadine/montelukast (Primary) ; Pseudoephedrine
Indications Seasonal allergic rhinitis
Focus Registrational; Therapeutic Use
Acronyms Study P04095

Most Recent Events

01 May 2009 Primary endpoint 'Symptom score' has been met.
27 Jun 2008 Schering-Plough and Merck and Co withdraw NDA for loratadine/montelukast combination tablet according to Schering-Plough media release.
05 Sep 2006 Status change

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com